300149 睿智医药
2026/06 - 中期
人民币(K¥)
2025/12
人民币(K¥)
2024/12
人民币(K¥)
2023/12
人民币(K¥)
2022/12
人民币(K¥)
经营活动产生之现金流量净额39,969190,499168,207150,992262,460
投资活动产生之现金流量净额(9,254)(69,905)(67,668)(12,820)1,007,779
筹资活动产生之现金流量净额(30,816)(79,711)(86,436)(388,341)(860,110)
汇率变动对现金及现金等价物的影响(15,277)1,1507,1176,97522,301
现金及现金等价物净增加/(减少)(15,378)42,03321,219(243,194)432,431
期初现金及现金等价物余额405,481363,449342,229585,424152,993
期末现金及现金等价物余额390,103405,481363,449342,229585,424